大多數實體瘤的生長依賴於“基質”的重塑，基質由癌症相關成纖維細胞(CAF) 和細胞外基質(ECM) 組成，在腫瘤的發生、進展、轉移和治療耐藥中發揮著關鍵作用。最近的研究清楚地表明，癌症相關成纖維細胞有效免疫抑制活性是基質促進腫瘤進展並賦予對免疫療法耐藥性的主要機制，造成癌症細胞有抗藥性的現象發生。
本研究發展出仿肺腫瘤微環境之生醫晶片探討成纖維細胞對癌症細胞以及免疫細胞測藥的影響，結合介電泳技術排列癌症細胞A549、纖維母細胞WI-38及免疫細胞Jurkat四種不同的細胞配置，單一癌症細胞外圍一圈免疫細胞、單一癌症細胞外圍一圈纖維母細胞及最外圍一圈免疫細胞、癌症細胞混合纖維母細胞外圍一圈纖維母細胞及最外圍一圈免疫細胞、癌症細胞混合纖維母細胞外圍一圈免疫細胞搭配生物相容性材料GelMA水膠，並使用化療藥物Pemetrexed以及免疫藥物Pembrolizumab和聯合藥物Pemetrexed + Pembrolizumab測藥分析。
在實驗結果顯示出，在化療藥物的治療下，存在WI-38纖維母細胞的腔室中，癌症細胞A549的死亡數相對其他沒有纖維母細胞的腔室低，且有一圈纖維母細胞繞的細胞配置下更降低癌症細胞的死亡數，死亡數量差有高達2000顆以上，在免疫藥物的治療結果中，存在一圈環繞的WI-38纖維母細胞會降低Jurkat免疫細胞遷移至癌症細胞區域的數量，根據免疫細胞遷移的數量多寡會直接影響癌症細胞死亡的數量，越多遷移的免疫細胞造成越多死亡的癌症細胞，在聯合療法的結果中，聯合療法顯示出有高於單一使用化療藥物及免疫藥物的效果，造成A549癌症細胞的死亡率有高達45% ~ 60%，化療藥物的死亡率在25% ~ 40%，而免疫藥物的死亡率為4% ~ 20%，且不管是哪一種藥物治療的結果中都顯示出存在WI-38纖維母細胞的環境中，都會降低癌症細胞A549的死亡率，印證存在纖維母細胞中促使癌症細胞具有抗藥性的現象。此晶片產生了四種細胞配置的腫瘤微環境，針對抗藥性的現象提供了一個有利的工具，期望未來能應用此晶片提供病患在臨床上及時用藥的檢測平台，降低臨床上病患的死亡率。

Recent studies have clearly shown that the potent immunosuppressive activity of cancer-associated fibroblasts is a major mechanism by which stroma promotes tumor progression and confers resistance to immunotherapy, resulting in drug-resistant cancer cells.
This study developed a microfluidic chip that mimics the lung tumor microenvironment to investigate the impact of fibroblasts on cancer cells and immune cells for drug testing. It combined dielectrophoresis technology to arrange four cell configurations of cancer cells A549, fibroblasts WI-38, and immune cells Jurkat. This chip is combined with the biocompatible material GelMA hydrocolloid. The chemotherapy drug Pemetrexed, and the immune drug Pembrolizumab were used for drug testing analysis.
Experimental results show that under treatment with chemotherapy drugs, the death of cancer cells in the chamber containing fibroblasts is lower than that in other chambers without fibroblasts. In the cell chamber surrounded by a circle of fibroblasts, the death number of cancer cells dropped even more drastically, and the difference in the number of deaths was as high as more than 2,000. In the treatment results of immune drugs, the number of immune cells migrating to the cancer cell area in the chamber surrounded by a ring of fibroblasts was significantly reduced. The more migrating immune cells cause more dead cancer cells. In combination therapy results, combination therapy shows higher mortality than the single use of chemotherapy and immune drugs.
Regardless of the drug treatment, the results show that the presence of fibroblasts in the environment will reduce the mortality of cancer cells. This chip generates four types of cell configurations that simulate tumor microenvironments, providing a favorable testing platform for drug resistance. This chip is expected to be used to provide a detection platform for patients to take medicine promptly in clinical practice, which can reduce the mortality rate of clinical patients.

[1] https://www.hpa.gov.tw/Pages/List.aspx?nodeid=4053
[2] Richard Doll, and A. Bradford Hill, “Smoking and Carcinoma of the Lung,” British Medical Journal, 1950, 2, (4682), pp. 739-748
[3] Feifei Huang, Bing Pan, Jun Wu, Engeng Chen, and Liying Chen, “Relationship between exposure to PM2. 5 and lung cancer incidence and mortality: A meta-analysis,” Oncotarget, 2017, 8, (26), pp. 43322
[4] https://web.commonhealth.com.tw/lungcancer2021/#keynumber
[5] https://www.hpa.gov.tw/Pages/List.aspx?nodeid=4056
[6] Andreas Manz, D Jed Harrison, Elisabeth MJ Verpoorte, James C Fettinger, Aran Paulus, Hans Lüdi, and H Michael Widmer, “Planar chips technology for miniaturization and integration of separation techniques into monitoring systems: capillary electrophoresis on a chip,” Journal of Chromatography A, 1992, 593, (1-2), pp. 253-258
[7] Tarek Saydé, Omar El Hamoui, Bruno Alies, Karen Gaudin, Gaetane Lespes, and Serge Battu, “Biomaterials for three-dimensional cell culture: From applications in oncology to nanotechnology,” Nanomaterials, 2021, 11, (2), pp. 481
[8] Mahdi Karimi, Sajad Bahrami, Hamed Mirshekari, Seyed Masoud Moosavi Basri, Amirala Bakhshian Nik, Amir R Aref, Mohsen Akbari, and Michael R Hamblin, “Microfluidic systems for stem cell-based neural tissue engineering,” Lab on a Chip, 2016, 16, (14), pp. 2551-2571
[9] Jensen C and Teng Y, “Is It Time to Start Transitioning From 2D to 3D Cell Culture? ,” Front Mol Biosci., 2020
[10] Šeila Selimović, Mehmet R Dokmeci, and Ali Khademhosseini, “Organs-on-a-chip for drug discovery,” Current opinion in pharmacology, 2013, 13, (5), pp. 829-833
[11] Karolina P Valente, Sultan Khetani, Ahmad R Kolahchi, Amir Sanati-Nezhad, Afzal Suleman, and Mohsen Akbari, “Microfluidic technologies for anticancer drug studies,” Drug discovery today, 2017, 22, (11), pp. 1654-1670
[12] Corey J Langer, Benjamin Besse, Antonio Gualberto, Elizabeth Brambilla, and Jean-Charles Soria, “The evolving role of histology in the management of advanced non–small-cell lung cancer,” Journal of clinical oncology, 2010, 28, (36), pp. 5311-5320
[13] Troy Stevens, Sem Phan, Maria G Frid, Diego Alvarez, Erica Herzog, and Kurt R Stenmark, “Lung vascular cell heterogeneity: endothelium, smooth muscle, and fibroblasts,” Proceedings of the American Thoracic Society, 2008, 5, (7), pp. 783-791
[14] Bi-Sen Ding, Daniel J Nolan, Peipei Guo, Alexander O Babazadeh, Zhongwei Cao, Zev Rosenwaks, Ronald G Crystal, Michael Simons, Thomas N Sato, and Stefan Worgall, “Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization,” Cell, 2011, 147, (3), pp. 539-553
[15] Nasser K Altorki, Geoffrey J Markowitz, Dingcheng Gao, Jeffrey L Port, Ashish Saxena, Brendon Stiles, Timothy McGraw, and Vivek Mittal, “The lung microenvironment: an important regulator of tumour growth and metastasis,” Nature Reviews Cancer, 2019, 19, (1), pp. 9-31
[16] Douglas Hanahan, and Lisa M Coussens, “Accessories to the crime: functions of cells recruited to the tumor microenvironment,” Cancer cell, 2012, 21, (3), pp. 309-322
[17] Robert O. Dillman ,“Cancer Immunotherapy,” Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, (1), pp. 1-64
[18] Federica Cavallo, Carla De Giovanni, Patrizia Nanni, Guido Forni, and Pier-Luigi Lollini, “2011: the immune hallmarks of cancer,” Cancer Immunology, Immunotherapy, 2011, 60, (3), pp. 319-326
[19] Mary Ann Warren, Suzanne F Shoemaker, David J Shealy, Wiam Bshara, and Margot M Ip, “Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic miceTNF Loss Inhibits Mammary Tumor Development and Growth,” Molecular cancer therapeutics, 2009, 8, (9), pp. 2655-2663
[20] Mario P Colombo, and Silvia Piconese, “Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy,” Nature Reviews Cancer, 2007, 7, (11), pp. 880-887
[21] Angela Vasaturo, Stefania Di Blasio, Deborah GA Peeters, Coco CH De Koning, Jolanda M de Vries, Carl G Figdor, and Stanleyson V Hato, “Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go,” Frontiers in immunology, 2013, 4, pp. 417
[22] Jieying Zhang, Zhaopeng Shi, Xiang Xu, Zuoren Yu, and Jun Mi, “The influence of microenvironment on tumor immunotherapy,” The FEBS Journal, 2019, 286, (21), pp. 4160-4175
[23] Roghayyeh Baghban, Leila Roshangar, Rana Jahanban-Esfahlan, Khaled Seidi, Abbas Ebrahimi-Kalan, Mehdi Jaymand, Saeed Kolahian, Tahereh Javaheri, and Peyman Zare, “Tumor microenvironment complexity and therapeutic implications at a glance,” Cell Communication and Signaling, 2020, 18, pp. 1-19
[24] Raghu Kalluri, “The biology and function of fibroblasts in cancer,” Nature Reviews Cancer, 2016, 16, (9), pp. 582-598
[25] Limin Wang, Limin Cao, Huimin Wang, Boning Liu, Qicheng Zhang, Zhaowei Meng, Xiang Wu, Qinghua Zhou, and Ke Xu, “Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway,” Oncotarget, 2017, 8, (44), pp. 76116
[26] Jun Zhang, and Nirmal Veeramachaneni, “Targeting interleukin-1β and inflammation in lung cancer,” Biomarker research, 2022, 10, (1), pp. 5
[27] Michael R Nazareth, Lori Broderick, Michelle R Simpson-Abelson, Raymond J Kelleher, Sandra J Yokota, and Richard B Bankert, “Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells,” The Journal of Immunology, 2007, 178, (9), pp. 5552-5562
[28] Richard Lee Barrett, and Ellen Puré, “Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy,” Elife, 2020, 9, pp. e57243
[29] Alfie T. Baker, Mohammed H. Abuwarwar, Lylarath Poly, Simon Wilkins, and Anne L. Fletcher, “Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes,” The Journal of Immunology, 2021, 206, (2), pp. 310-320
[30] Brent Johnston, and Eugene C Butcher, “ Chemokines in rapid leukocyte adhesion triggering and migration,” in Editor (Ed.)^(Eds.): 'Book Chemokines in rapid leukocyte adhesion triggering and migration' (Elsevier, 2002, edn.), pp. 83-92
[31] Hongmei Fu, Eleanor Jayne Ward, and Federica M Marelli-Berg, “Mechanisms of T cell organotropism,” Cellular and Molecular Life Sciences, 2016, 73, pp. 3009-3033
[32] Yu-Chih Chen, Steven G Allen, Patrick N Ingram, Ronald Buckanovich, Sofia D Merajver, and Euisik Yoon, “Single-cell migration chip for chemotaxis-based microfluidic selection of heterogeneous cell populations,” Scientific reports, 2015, 5, (1), pp. 9980
[33] Fu-Qiang Nie, Masumi Yamada, Jun Kobayashi, Masayuki Yamato, Akihiko Kikuchi, and Teruo Okano, “On-chip cell migration assay using microfluidic channels,” Biomaterials, 2007, 28, (27), pp. 4017-4022
[34] Han-Jung Liao, Jean-An Chieh, Yu-Chen Chen, Kang-Yun Lee, Yao-Fei Chan, Shu-Chuan Ho, Wei-lun Sun, Yu-Shiuan Wang, Wan-Chen Huang, and Wei-Chiao Chang, “ Lung cancer on chip for testing immunotherapy,”in Editor (Ed.)^(Eds.): 'Book Lung cancer on chip for testing immunotherapy' (IEEE, 2021, edn.), pp. 1032-1035
[35] Manguo Huang, Shangchun Fan, Weiwei Xing, and Changting Liu, “Microfluidic cell culture system studies and computational fluid dynamics,” Mathematical and Computer Modelling, 2010, 52, (11-12), pp. 2036-2042
[36] Younan Xia, and George M Whitesides, “Soft lithography,” Angewandte Chemie International Edition, 1998, 37, (5), pp. 550-575
[37] Anas Alazzam, Ion Stiharu, Rama Bhat, and Ari‐Nareg Meguerditchian, “Interdigitated comb‐like electrodes for continuous separation of malignant cells from blood using dielectrophoresis,” Electrophoresis, 2011, 32, (11), pp. 1327-1336
[38] Hongjun Song, Jenna M Rosano, Yi Wang, Charles J Garson, Balabhaskar Prabhakarpandian, Kapil Pant, George J Klarmann, Alan Perantoni, Luis M Alvarez, and Eva Lai, “Continuous-flow sorting of stem cells and differentiation products based on dielectrophoresis,” Lab on a Chip, 2015, 15, (5), pp. 1320-1328
[39] Mohamed Z Rashed, and Stuart J Williams, “Advances and applications of isomotive dielectrophoresis for cell analysis,” Analytical and Bioanalytical Chemistry, 2020, 412, (16), pp. 3813-3833
[40] Nurhaslina Abd Rahman, Fatimah Ibrahim, and Bashar Yafouz, “Dielectrophoresis for biomedical sciences applications: A review,” Sensors, 2017, 17, (3), pp. 449
[41] https://www.atcc.org/products/ccl-185
[42] https://www.atcc.org/products/ccl-75
[43] https://www.atcc.org/products/tib-152
[44] Iliyana Pepelanova, Katharina Kruppa, Thomas Scheper, and Antonina Lavrentieva, “Gelatin-methacryloyl (GelMA) hydrogels with defined degree of functionalization as a versatile toolkit for 3D cell culture and extrusion bioprinting,” Bioengineering, 2018, 5, (3), pp. 55
[45] Kristan D Rollins, and Celeste Lindley, “Pemetrexed: a multitargeted antifolate,” Clinical therapeutics, 2005, 27, (9), pp. 1343-1382
[46] Leila Khoja, Marcus O Butler, S Peter Kang, Scot Ebbinghaus, and Anthony M Joshua, “Pembrolizumab,” Journal for immunotherapy of cancer, 2015, 3, pp. 1-13